Prostate cancer screening for carriers and noncarriers of pathogenic variants of the BRCA1 and BRCA2 genes identified a higher proportion of clinically relevant disease in the carrier groups. Prostate-specific antigen screening should be recommended for carriers of BRCA1 and BRCA2 pathogenic variants.
European Urology published a clinical update in Research Highlights on 18 Feb 2026.
The item focuses on Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.
Review the original article for the full source wording and details.